Filtered By:
Management: Medicare
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 992 results found since Jan 2013.
Formulary restrictions and stroke risk in patients with atrial fibrillation
CONCLUSIONS: Limiting access to NOACs may exacerbate current underuse of anticoagulants and increase the risk of stroke among patients with newly diagnosed AF. Pharmacy benefit managers and Part D plans need to continuously review the appropriateness of formulary policies to ensure patient access to effective medications.PMID:36252171 | DOI:10.37765/ajmc.2022.89195
Source: The American Journal of Managed Care - October 17, 2022 Category: Health Management Authors: Bo Zhou Seth Seabury Dana Goldman Geoffrey Joyce Source Type: research
High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial
Vaccine. 2022 Oct 13:S0264-410X(22)01215-4. doi: 10.1016/j.vaccine.2022.09.085. Online ahead of print.ABSTRACTOlder adults are at high risk of major acute cardiovascular events (MACE) linked to influenza illness andpreventable by influenza vaccination. It is unknown whether high-dose vaccine might incrementally reduce the risk of MACE.We conducted a post-hoc analysis of data collected from a pragmatic cluster randomized study of 823 nursing homes (NH) randomized to standard-dose (SD) or high-dose (HD) influenza vaccine in the 2013-14 season. Adults age 65 year or older who are Medicare-enrolled long-stay residents were inc...
Source: Vaccine - October 16, 2022 Category: Allergy & Immunology Authors: Elie A Saade Yasin Abul Kevin McConeghy H Edward Davidson Lisa Han Nina Joyce David H Canaday Leon Hsueh Elliott Bosco Stefan Gravenstein Source Type: research
Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis
CONCLUSION: Results indicate high clinical need and economic burden among patients with severe presentation of SCD. These findings not only highlight the need for improved therapeutic options to limit or prevent disease progression, but also starts to provide insight on lifetime costs of SCD that will be needed in the evaluation of emerging curative intent therapies.PMID:36222016 | DOI:10.1080/13696998.2022.2133824
Source: Journal of Medical Economics - October 12, 2022 Category: Health Management Authors: Meghan Gallagher Anjulika Chawla Brenna L Brady Sherif M Badawy Source Type: research
